Initial results of dose escalation of ISB 1342, a novel CD3xCD38 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) Meeting Abstract
| Authors: | Mohan, S. R.; Chase, C. C.; Berdeja, J. G.; Karlin, L.; Belhadj, K.; Perrot, A.; Moreau, P.; Touzeau, C.; Chalopin, T.; Lesokhin, A. M.; Huff, C. A.; Vesole, D. H.; Richter, J.; Matous, J. V.; Proscurshim, I.; Wolff, E.; Gudi, G.; Garton, A.; Menon, V.; Gn, S.; Salhi, Y.; Feldman, E. J.; Mohty, M. |
| Abstract Title: | Initial results of dose escalation of ISB 1342, a novel CD3xCD38 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 7264 |
| End Page: | 7266 |
| Language: | English |
| ACCESSION: | WOS:000893230300123 |
| DOI: | 10.1182/blood-2022-157525 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) -- DEC 10-13, 2022 -- New Orleans, LA -- 1 -- Source: Wos |
